Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings or view top-rated stocks.

8 analysts have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $14.00 to $87.00. On average, they predict the company's share price to reach $38.50 in the next year. This suggests a possible upside of 243.4% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 at the start of the year. Since then, ENTA stock has decreased by 75.9% and is now trading at $11.21.
View the best growth stocks for 2023 here.

Enanta Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,050,000 shares, an increase of 22.0% from the August 31st total of 1,680,000 shares. Based on an average trading volume of 395,800 shares, the short-interest ratio is presently 5.2 days. Currently, 10.5% of the company's shares are sold short.
View Enanta Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its earnings results on Monday, August, 7th. The biotechnology company reported ($1.86) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $0.52. The biotechnology company had revenue of $18.89 million for the quarter, compared to analyst estimates of $15.88 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 46.77% and a negative net margin of 163.87%.

ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

Enanta Pharmaceuticals issued an update on its third quarter earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of ($1.86) for the period, compared to the consensus EPS estimate of ($2.25). The company issued revenue guidance of $18.9 million, compared to the consensus revenue estimate of $18.19 million.

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $11.21.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $236.08 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($6.31) on an earnings per share basis.

The company employs 160 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.